STOCK TITAN

FENNEC PHARMACEUTICALS (FENC) SEC Filings, Aug 3-31, 2026

FENC NASDAQ

Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.

The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.

Rhea-AI Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported an insider equity transaction by Chief Financial Officer Robert Andrade. On 2026-08-31, Andrade acquired 1,703 common shares at a reported price of $0.00 per share, characterized as a grant or award. A footnote states these shares represent releases from restrictions on shares originally awarded on 2024-05-16 and 2025-03-28. Following this release, Andrade directly holds 241,306 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
insider
-
Rhea-AI Summary

FENNEC PHARMACEUTICALS INC. (FENC) received a Form 144 notice from officer Pierre S. Sayad covering a proposed sale of 12,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The notice cites an aggregate market value of $146,169.60 and references 35,067,159 common shares outstanding. The shares relate to performance shares and restricted stock scheduled to vest in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
other
-
Rhea-AI Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported insider activity by Chief Financial Officer Robert Andrade. On August 28, 2026, he exercised 21,928 stock options at an exercise price of $5.10 per share, acquiring the same number of common shares, and held 779,330 stock options directly after this exercise. On August 27, 2026, he sold 75,000 common shares at $11.78 per share pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026, with a portion of the proceeds used to pay his tax obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
insider
Rhea-AI Summary

FENNEC PHARMACEUTICALS INC. (FENC) received a Form 144 notice indicating that officer Robert Andrade plans to sell 75,000 shares of Fennec common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC – Executive Financial Services, with an indicated aggregate market value of $883,897.50 and trading on NASDAQ.

The shares to be sold were acquired directly from the issuer upon the exercise of stock options for cash during the period from 08/13/2020 through 03/26/2026. A notice date of 08/27/2026 is reported, and no prior three‑month sales are listed in the disclosure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
other
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. received an amended Schedule 13G (Amendment No. 3) from a group of Southpoint-related entities and individual John S. Clark regarding its Common Shares, no par value. The reporting persons – Southpoint Master Fund, LP; Southpoint Capital Advisors LP; Southpoint Capital Advisors LLC; Southpoint GP, LP; Southpoint GP, LLC; and John S. Clark – each report 0 Common Shares beneficially owned, with 0% of the class and no sole or shared voting or dispositive power. They indicate they now hold ownership of 5 percent or less of the class. The filing is signed by John S. Clark II in multiple related capacities on August 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
ownership
-
Rhea-AI Summary

Solas Capital Management, LLC and Frederick Tucker Golden report beneficial ownership of Fennec Pharmaceuticals Inc. common shares. They each report 1,889,366 shares of common stock, representing 5.4% of the class, held through a fund and another private fund they manage. The percentage is based on 34,737,030 shares outstanding as of May 12, 2026. They report no sole voting or dispositive power, but shared voting and shared dispositive power over all 1,889,366 shares. The funds themselves expressly disclaim beneficial ownership of the reported securities under Rule 13d-4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
ownership
Rhea-AI Summary

Fennec Pharmaceuticals reported strong growth and a shift to profitability driven by commercialization of PEDMARK®. For the quarter ended June 30, 2026, total revenue was $17.9 million, up from $9.7 million a year earlier, including PEDMARK net product sales of $17.2 million and $0.7 million of other revenue from its PEDMARQSI® license with Norgine.

Quarterly income from operations was $1.7 million versus a loss of $2.7 million, and net income was $2.0 million versus a net loss of $3.2 million. For the first six months of 2026, revenue reached $33.0 million, with net income of $2.2 million compared to a $4.3 million loss in 2025, and operating cash flow improved to $2.4 million.

Growth was accompanied by a sharp increase in selling and marketing expense to $10.7 million in the quarter, reflecting continued U.S. commercialization and support for international expansion through Norgine. Fennec ended June 30, 2026 with $41.2 million in cash and cash equivalents and $42.4 million of stockholders’ equity, and believes existing cash plus expected revenues will fund operations for at least the next twelve months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
quarterly report
-
Rhea-AI Summary

Fennec Pharmaceuticals Inc. received an updated ownership report from Rosalind Advisors Inc. and related parties. They report beneficial ownership of up to 3,321,333 common shares, representing 9.6% of Fennec’s common stock, based on 34,737,030 shares outstanding as of May 12, 2026.

Rosalind Master Fund L.P. holds 3,188,001 shares with shared voting and dispositive power, while Steven Salamon and Gilad Aharon each have sole voting and dispositive power over 66,666 shares plus shared power over 3,188,001 shares. Rosalind Advisors and Mr. Salamon may be deemed beneficial owners but both disclaim beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
ownership
-
Rhea-AI Summary

FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov sold 10,000 common shares on 2026-08-03 at $9.5800 per share in a sale classified as an open-market or private transaction. The sale was executed under a Rule 10b5-1 plan dated September 19, 2025, and left him holding 131,633 common shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.06%
Tags
insider
Rhea-AI Summary

FENC shareholder Rostislav Raykov filed to sell 10,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after 08/03/2026 on NASDAQ. The shares were acquired as Restricted Stock from the issuer on 11/30/2025, and prior sales in the last three months totaled 19,346 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.42%
Tags
other

FAQ

How many FENNEC PHARMACEUTICALS (FENC) SEC filings are available on StockTitan?

StockTitan tracks 149 SEC filings for FENNEC PHARMACEUTICALS (FENC), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for FENNEC PHARMACEUTICALS (FENC)?

The most recent SEC filing for FENNEC PHARMACEUTICALS (FENC) was filed on November 16, 2026.